FDA panel endorses Aegerion HoFH drug, but concerns raised over off-label use
This article was originally published in Scrip
Executive Summary
A US FDA panel of advisers on 17 October backed approval of Aegerion Pharmaceuticals' cholesterol-lowering drug lomitapide to treat a rare genetic lipid disorder, homozygous familial hypercholesterolemia (HoFH), in which patients develop cardiovascular disease before age 20 - dying typically before 30.